Our Cancer Screening & Risk tests provide advanced insights into genetic and biological markers that can influence your risk or reveal early signs of cancer.
This category includes EPISEEK, a cutting-edge Precision Epigenomics test that analyzes subtle DNA methylation patterns associated with early-stage cancers.
It also features the Prostate Health Index (PHI) — a next-generation assessment combining multiple PSA markers for a clearer, more accurate evaluation of prostate cancer risk.
Additionally, our Cancer Antigen (CA) panels, performed through Mayo Clinic Laboratories, offer trusted diagnostic accuracy for markers such as CA 125, CA 15-3, and CEA, supporting ongoing monitoring and early detection.
Display prices in:CAD